110 related articles for article (PubMed ID: 16317430)
21. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.
Blank S; Rachakonda S; Keller G; Weichert W; Lordick F; Langer R; Springfeld C; Bruckner T; Becker K; Kumar R; Ott K
BMC Cancer; 2014 Feb; 14():58. PubMed ID: 24490800
[TBL] [Abstract][Full Text] [Related]
22. Sinomenine sensitizes gastric cancer cells to 5-fluorouracil
Liao F; Yang Z; Lu X; Guo X; Dong W
Oncol Lett; 2013 Dec; 6(6):1604-1610. PubMed ID: 24260052
[TBL] [Abstract][Full Text] [Related]
23. A bioactive probe for glutathione-dependent antioxidant capacity in breast cancer patients: implications in measuring biological effects of arsenic compounds.
Li J; Zhang D; Jefferson PA; Ward KM; Ayene IS
J Pharmacol Toxicol Methods; 2014; 69(1):39-48. PubMed ID: 24149024
[TBL] [Abstract][Full Text] [Related]
24. A pilot study to investigate the role of thymidylate synthase as a marker of prognosis for neoadjuvant chemotherapy in gastric and gastro-oesophageal junction adenocarcinoma.
Mirza A; Brown M; McNulty C; Valentine J; Annesley A; Galloway S; Welch I; West CM; Pritchard S
Gastroenterol Res Pract; 2013; 2013():502153. PubMed ID: 23533389
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review.
Wang Z; Chen JQ; Liu JL; Qin XG; Huang Y
BMC Gastroenterol; 2012 Sep; 12():137. PubMed ID: 23020798
[TBL] [Abstract][Full Text] [Related]
26. Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not?
Valachis A; Mauri D; Neophytou C; Polyzos NP; Tsali L; Garras A; Papanikolau EG
Int J Med Sci; 2011; 8(6):492-500. PubMed ID: 21897762
[TBL] [Abstract][Full Text] [Related]
27. Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.
Deenen MJ; Cats A; Beijnen JH; Schellens JH
Oncologist; 2011; 16(7):1006-20. PubMed ID: 21659612
[TBL] [Abstract][Full Text] [Related]
28. Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.
Deenen MJ; Cats A; Beijnen JH; Schellens JH
Oncologist; 2011; 16(7):992-1005. PubMed ID: 21659608
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.
Li QF; Yao RY; Liu KW; Lv HY; Jiang T; Liang J
J Korean Med Sci; 2010 Jun; 25(6):846-52. PubMed ID: 20514304
[TBL] [Abstract][Full Text] [Related]
30. Effects of Genetic Polymorphisms of Glutathione S-transferase P1 on Helicobacter pylori-associated Gastric Cancer.
Kang JM; Kim N; Cho SI; Lee DH; Park YS; Kim YR; Park JH; Lee MK; Kim JS; Jung HC; Song IS
Gut Liver; 2008 Jun; 2(1):23-9. PubMed ID: 20485607
[TBL] [Abstract][Full Text] [Related]
31. Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients.
Kilburn L; Okcu MF; Wang T; Cao Y; Renfro-Spelman A; Aldape KD; Gilbert MR; Bondy M
Cancer; 2010 May; 116(9):2242-9. PubMed ID: 20187096
[TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.
Sissung TM; English BC; Venzon D; Figg WD; Deeken JF
Pharmacogenomics; 2010 Jan; 11(1):89-103. PubMed ID: 20017675
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer.
Grimminger PP; Stöhlmacher J; Vallböhmer D; Schneider PM; Hölscher AH; Metzger R; Danenberg PV; Brabender J
J Oncol; 2009; 2009():139590. PubMed ID: 20016751
[TBL] [Abstract][Full Text] [Related]
34. Expression of thymidylate synthase and glutathione-s-transferase pi in patients with esophageal squamous cell carcinoma.
Huang JX; Li FY; Xiao W; Song ZX; Qian RY; Chen P; Salminen E
World J Gastroenterol; 2009 Sep; 15(34):4316-21. PubMed ID: 19750576
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenomics in chemotherapy for GI tract cancer.
Furuta T
J Gastroenterol; 2009; 44(10):1016-25. PubMed ID: 19728007
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms of thymidylate synthase in the 5'- and 3'-untranslated regions and gastric cancer.
Zhuang W; Wu XT; Zhou Y; Liu GJ; Wu TX; Yao X; Du L; Wei ML
Dig Dis Sci; 2009 Jul; 54(7):1379-85. PubMed ID: 18989779
[TBL] [Abstract][Full Text] [Related]
37. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.
Barahmani N; Carpentieri S; Li XN; Wang T; Cao Y; Howe L; Kilburn L; Chintagumpala M; Lau C; Okcu MF
Neuro Oncol; 2009 Jun; 11(3):292-300. PubMed ID: 18952980
[TBL] [Abstract][Full Text] [Related]
38. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
Kweekel DM; Koopman M; Antonini NF; Van der Straaten T; Nortier JW; Gelderblom H; Punt CJ; Guchelaar HJ
Br J Cancer; 2008 Oct; 99(8):1316-21. PubMed ID: 18797455
[TBL] [Abstract][Full Text] [Related]
39. Long-term platinum retention after treatment with cisplatin and oxaliplatin.
Brouwers EE; Huitema AD; Beijnen JH; Schellens JH
BMC Clin Pharmacol; 2008 Sep; 8():7. PubMed ID: 18796166
[TBL] [Abstract][Full Text] [Related]
40. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
Keam B; Im SA; Han SW; Ham HS; Kim MA; Oh DY; Lee SH; Kim JH; Kim DW; Kim TY; Heo DS; Kim WH; Bang YJ
BMC Cancer; 2008 May; 8():148. PubMed ID: 18505590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
